Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maraviroc versus efavirenz with zidovudine/lamivudine in treatment-naive CCR5-tropic HIV-1 infection
2004-001914-15Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of maraviroc in Human immunodeficiency virus infection type 1 (3 arms), sponsored by ViiV Healthcare. Primary endpoints: Virologic response at Week 48 (<400 copies/mL) and Virologic response at Week 48 (<50 copies/mL). Started Feb 2005; status: completed.
02
Drugs
maraviroc
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2004-001914-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001914-15.